Stay updated on BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial

Sign up to get notified when there's something new on the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The study record for the completed Phase 2 BTX 1204 atopic dermatitis trial is displayed, including its design, eligibility criteria, locations, and outcome measures.
    Difference
    60%
    Check dated 2026-11-10T17:57:55.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer’s revision identifier changes from v3.7.2 to v3.8.0, while the page remains a 403 Forbidden error screen.
    Difference
    0.2%
    Check dated 2026-11-03T18:21:54.000Z thumbnail image
  3. Check
    27 days ago
    Change Detected
    Summary
    An NIH-wide banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence,” and the site revision advances from v3.7.1 to v3.7.2. The study page itself continues to show a 403 error.
    Difference
    1%
    Check dated 2026-10-20T19:43:32.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    The site revision displayed on the 403 Forbidden error page changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T19:30:26.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, blocking access to the study record; the usual study content and navigation are replaced by an access-denied message.
    Difference
    18%
    Check dated 2026-09-22T22:24:45.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The page now shows a new site revision label, Revision: v3.7.0, replacing the previous Revision: v3.6.6. This indicates an update to the page framework or template that does not affect the study content or eligibility details.
    Difference
    0.0%
    Check dated 2026-09-15T21:59:22.000Z thumbnail image

Stay in the know with updates to BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page.